KR20200069261A - 항생제 마크로라이드를 전달하는 안구건조증을 치료하기 위한 조성물 및 방법 - Google Patents

항생제 마크로라이드를 전달하는 안구건조증을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20200069261A
KR20200069261A KR1020197038288A KR20197038288A KR20200069261A KR 20200069261 A KR20200069261 A KR 20200069261A KR 1020197038288 A KR1020197038288 A KR 1020197038288A KR 20197038288 A KR20197038288 A KR 20197038288A KR 20200069261 A KR20200069261 A KR 20200069261A
Authority
KR
South Korea
Prior art keywords
composition
type
active agent
days
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197038288A
Other languages
English (en)
Korean (ko)
Inventor
이샤이 아타르
아이알 쉐렛
Original Assignee
엑시모어 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑시모어 엘티디. filed Critical 엑시모어 엘티디.
Publication of KR20200069261A publication Critical patent/KR20200069261A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020197038288A 2017-05-30 2018-05-30 항생제 마크로라이드를 전달하는 안구건조증을 치료하기 위한 조성물 및 방법 Ceased KR20200069261A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762512682P 2017-05-30 2017-05-30
US62/512,682 2017-05-30
PCT/IB2018/000693 WO2018220444A2 (en) 2017-05-30 2018-05-30 Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide

Publications (1)

Publication Number Publication Date
KR20200069261A true KR20200069261A (ko) 2020-06-16

Family

ID=64456159

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197038288A Ceased KR20200069261A (ko) 2017-05-30 2018-05-30 항생제 마크로라이드를 전달하는 안구건조증을 치료하기 위한 조성물 및 방법

Country Status (7)

Country Link
US (1) US20200147055A1 (https=)
EP (1) EP3630042A4 (https=)
JP (2) JP7278969B2 (https=)
KR (1) KR20200069261A (https=)
CN (1) CN111278401B (https=)
CA (1) CA3065474A1 (https=)
WO (1) WO2018220444A2 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022096931A2 (en) * 2020-11-09 2022-05-12 Eximore Ltd. Punctal plugs containing micelle-encapsulated ophthalmic pharmaceuticals and methods for making thereof
WO2024069230A2 (en) * 2022-09-29 2024-04-04 Eximore Ltd. Ophthalmic compositions and methods for sustained drug release

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
AU777915B2 (en) * 1999-04-30 2004-11-04 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
US20030018044A1 (en) * 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
US6489335B2 (en) * 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
CA2539324A1 (en) * 2003-09-18 2005-03-31 Macusight, Inc. Transscleral delivery
US7087237B2 (en) * 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
CN101437478A (zh) * 2004-10-04 2009-05-20 Qlt美国有限公司 聚合送递制剂的眼部送递
DE602004017477D1 (de) * 2004-11-09 2008-12-11 Novagali Pharma Sa Öl-in-Wasser-Emulsion mit niedriger Konzentration des kationischen Mittels und positivem Zetapotential
JP4974903B2 (ja) * 2005-02-09 2012-07-11 参天製薬株式会社 疾患または状態を処置するための液体処方物
EP2004172B1 (en) * 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
UY30883A1 (es) * 2007-01-31 2008-05-31 Alcon Res Tapones punctales y metodos de liberacion de agentes terapeuticos
EP2320972B1 (en) * 2008-05-08 2020-07-01 MiniPumps, LLC Implantable drug-delivery devices
EP2376019A1 (en) * 2008-12-19 2011-10-19 QLT, Inc. Substance delivering punctum implants and methods
AU2011235002B2 (en) * 2010-03-31 2016-08-11 Ocuject, Llc Device and method for intraocular drug delivery
CA2798084A1 (en) * 2010-05-17 2011-11-24 Aerie Pharmaceuticals, Inc. Drug delivery devices for delivery of ocular therapeutic agents
ES2727203T3 (es) * 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
EP2916827B1 (en) * 2012-11-08 2020-06-10 Clearside Biomedical Inc. Methods for the treatment of ocular disease in human subjects
MX364310B (es) * 2013-11-05 2019-04-22 Gustavo A Garcia Sanchez Método para preparar una formulación inmunosupresora.
WO2016083891A1 (en) * 2014-11-25 2016-06-02 Eyal Sheetrit Compositions and methods for delivering a bio-active agent or bio-active agents

Also Published As

Publication number Publication date
CA3065474A1 (en) 2018-12-06
JP2023113647A (ja) 2023-08-16
JP7278969B2 (ja) 2023-05-22
WO2018220444A2 (en) 2018-12-06
US20200147055A1 (en) 2020-05-14
EP3630042A2 (en) 2020-04-08
JP7682226B2 (ja) 2025-05-23
JP2020521790A (ja) 2020-07-27
CN111278401B (zh) 2023-08-15
CN111278401A (zh) 2020-06-12
EP3630042A4 (en) 2021-06-23
WO2018220444A3 (en) 2019-02-28

Similar Documents

Publication Publication Date Title
US11013719B2 (en) Sunitinib formulations and methods for use thereof in treatment of glaucoma
US12318394B2 (en) Devices and methods for delivering a bio-active agent or bio-active agents
JP7682226B2 (ja) ドライアイ症候群を治療するための抗生物質マクロライドを送達する組成物および方法
CA2960213C (en) Methods and biocompatible compositions to achieve sustained drug release in the eye
KR20030009447A (ko) 지속 방출 약물 전달 장치, 그의 사용 방법 및 그의 제조방법
CN103494765A (zh) 多孔硅药物洗脱颗粒
KR102004014B1 (ko) 약물 전달 시스템
ES2365552T3 (es) Sistema de administración vaginal.
Attia et al. Design and evaluation of ciprofloxacin hydrochloride ocular inserts
WO2024069230A2 (en) Ophthalmic compositions and methods for sustained drug release

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191224

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210428

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230619

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20230925

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230619

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I